Autolus Therapeutics to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8
Management will host a conference call at
The call may also be accessed by dialing (866) 679-5407 for U.S. and
About
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: https://www.autolus.com.
Investor relations contact:
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com
Media contact:
Vice President, Corporate Affairs and Communications, Autolus
+1-240-801-3850
s.taylor@autolus.com
Media contact (
JW Communications
+44 (0) 7818 430877
juliawilsonuk@gmail.com
Source: Autolus Therapeutics plc